Juan Andres - Nov 5, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Nov 5, 2021
Transactions value $
-$4,432,650
Form type
4
Date filed
11/9/2021, 03:36 PM
Previous filing
Nov 5, 2021
Next filing
Nov 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K Nov 5, 2021 Direct F1
transaction MRNA Common Stock Sale -$1.2M -5K -100% $240.00 0 Nov 5, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $142K +10K $14.22* 10K Nov 8, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K +50% $12.21* 15K Nov 8, 2021 Direct F1
transaction MRNA Common Stock Sale -$3.5M -15K -100% $233.13 0 Nov 8, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -4% $0.00 120K Nov 5, 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -14.57% $0.00 58.6K Nov 8, 2021 Common Stock 10K $14.22 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -4.17% $0.00 115K Nov 8, 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.
F3 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer